Scientific Reports · 2020 · 26 citations · 48 references
MedicineOncologyPharmacologyCell SignalingNeoplasiaSignal TransductionCancer Cell SignalingInflammation-associated CarcinogenesisInflammatory SignalingOncogenic Signaling PathwaysUrothelial CarcinomaBraf V600e MutationCancer Signaling PathwaysCyclooxygenase-2 PathwayErk SignalingExtracellular Signal-regulated Kinase PathwayGain-of-function AnalysisProstaglandin ProductionRaf-mek-erk Signaling
Abstract Cancer-promoting inflammation is an important event in cancer development. Canine urothelial carcinoma (cUC) overexpresses prostaglandin E 2 (PGE 2 ) and has a unique sensitivity to cyclooxygenase 2 (COX2)-inhibiting therapy. In addition, majority of cUC harbour BRAF V595E mutation. However, mechanisms underlying aberrant PGE 2 production in BRAF V595E cUC patients remain unclear. Drug screening revealed that inhibition of RAF/MEK/ERK pathway, p38 and JNK pathway reduced PGE 2 production in cUC cells. By pharmacological inhibition of the multiple components in the pathway, activation of the ERK MAPK pathway was shown to mediate overexpression of COX2 and production of PGE 2 in BRAF V595E cUC cells. In silico gain-of-function analysis of the BRAF mutation also implicated involvement of mutation in the process. The positive association between ERK activation and COX2 expression was further validated in the clinical patients. Moreover, it was also suggested that p38 and JNK regulates PGE 2 production independently of ERK pathway, possibly through COX2-dependent and COX1-/COX2- independent manner, respectively. In conclusion, this study demonstrated that activation of ERK induces production of PGE 2 in BRAF V595E cUC cells, which is also independently regulated by p38 and JNK. With its unique vulnerability to COX-targeted therapy, BRAF V595E cUC may serve as a valuable model to study the tumour-promoting inflammation.
48
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai, Kanyawim Kirtikara · Nature Protocols · 2006 · 3.7K citations
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text